Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction?  An Argument to Treat only High-Risk Patients

Stephen G. Ball, PhD;

Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction? An Argument to Treat only High-Risk Patients

January 1, 1996

Stephen G. Ball, PhD

Publication

Article

Supplements and Featured PublicationsAdvances in Cardiovascular Therapeutics: Trends in ACE Inhibition

Volume 2

Issue 1 Suppl

Download PDF: Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction? An Argument to Treat only High-Risk Patients

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777